Clinical Trials

35 enrolled 10 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT06649331 2026-03-17

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04886531 2026-03-12

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

125 enrolled

Breast Neoplasms

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

37 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT04266249 2026-03-02

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

53 enrolled

Breast Neoplasms

NCT07053085 2026-02-27

A Study of Surgery and Radiotherapy in People With Breast Cancer

162 enrolled

Breast Neoplasms

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

20 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

512 enrolled 28 charts

Breast Neoplasms

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

120 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07402473 2026-02-11

EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer

50 enrolled

HER2-positive Early-stage Breast Cancer

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

240 enrolled 14 charts

Colonic Neoplasms, Rectal Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

36 enrolled

Stomach Neoplasms

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

28 enrolled

Advanced Cancer

NCT05730712 2026-02-06

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

7 enrolled

Genitourinary

Prostatic Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

23 enrolled 10 charts

Breast Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Colonic Neoplasms

NCT04661150 2026-01-30

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

42 enrolled 9 charts

Stomach Neoplasms

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Esophageal Neoplasms

NCT03765983 2026-01-22

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

17 enrolled

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT06468280 2026-01-21

ROSETTE

84 enrolled

Stomach Neoplasms

NCT07340398 2026-01-21

TAYLOR

200 enrolled

HER2-positive Early Breast Cancer

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT04721977 2026-01-09

MK-7119-001

66 enrolled 7 charts

Breast Neoplasms

NCT04578106 2026-01-06

ELPIS

5 enrolled 7 charts

Breast Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

720 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Breast Neoplasms

NCT03095352 2025-12-22

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

76 enrolled 14 charts

Breast Neoplasms

NCT02654119 2025-12-12

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

20 enrolled

Breast Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

13 enrolled

Breast Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT05180006 2025-12-01

BIS-Program

33 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

188 enrolled

Breast Neoplasms

NCT03571633 2025-11-26

BREASTIMMU02

90 enrolled

HER2-positive Breast Cancer

NCT01771458 2025-11-24

SHIVA

742 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

164 enrolled

Breast Neoplasms

NCT04733118 2025-11-20

PHERGAIN-2

393 enrolled